Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Article Details
- CitationCopy to clipboard
Belvedere S, Witter DJ, Yan J, Secrist JP, Richon V, Miller TA
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Bioorg Med Chem Lett. 2007 Jul 15;17(14):3969-71. Epub 2007 Apr 29.
- PubMed ID
- 17507219 [ View in PubMed]
- Abstract
Histone deacetylase (HDAC) inhibitors that target Class I and Class II HDACs are currently in advanced clinical trials for the treatment of cancer. Vorinostat (Zolinza, SAHA) is a hydroxamic acid approved for the treatment of patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. As part of an on-going effort to better understand the nature of the HDAC enzyme/inhibitor interaction and design highly effective HDAC inhibitors, we herein report the design, synthesis and HDAC inhibitory activity of a vorinostat-derived series of substrate-based HDAC inhibitors.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Vorinostat Histone deacetylase 1 IC 50 (nM) 48 N/A N/A Details